

# 1       **Public and pharmacist perceptions regarding counterfeit medicine in Lebanon using focus groups**

2

## 3       **Introduction**

4

5       Counterfeiting is a substantial problem that is growing worldwide and affects both developed and less  
6       developed countries (Alfadl et al. 2013). Counterfeit products are illegal, low priced and often of lower quality  
7       than their originals (Lai and Zaichkowsky 1999). When it is medicines being counterfeited, this is not only  
8       damaging to the pharmaceutical industries but also constitutes a significant threat to public health (Bird 2007).  
9       Counterfeiting in general represents around 5–7% of world trade, and around 10-30% of the global medicine  
10      supply chain could be counterfeit (UNODC 2006).

11      The incidence of counterfeit medicine (CFM) varies based on each country's regulatory and enforcement  
12      system. Poor and developing countries with weak regulatory and enforcement systems have higher percentages  
13      of CFM (Chauvé 2008; Alfadl et al. 2013; Rajapandian et al. 2013). Developed countries are less vulnerable  
14      to CFM and are considered properly regulated with well-controlled systems, yet several cases have been  
15      discovered within their legal pharmaceutical distribution chains (Besançon 2008).

16      The most common factors that encourage counterfeiters to produce CFM are: lack of legislation  
17      prohibiting counterfeiting of medicine; weak or minimum enforcement of laws and disciplinary actions; the  
18      high cost of branded medicine; and a shortage of medicine supplies (Chauvé 2008; Alfadl et al. 2013;  
19      Rajapandian et al. 2013; Al-Worafi 2014).

20      CFMs play a major role in destroying the public's trust in the healthcare team (Newton et al. 2006; Akiny  
21      2013) the safety and efficacy of pharmaceutical products (Newton et al. 2006); government and regulatory  
22      authorities in controlling the availability of CFM (Akiny 2013; Mdege et al. 2016). Moreover, ignorance of  
23      the risks and attributes of CFMs increases the vulnerability towards CFM use, causing lower detection and  
24      reporting rates for counterfeits (Akiny 2013).

25      The problem of CFM continues and the crisis of medicine shortages is still present, however, currently the  
26      economic, political, governmental and regulatory situations of each country, add to the reasons why CFMs are  
27      more readily available in some countries more than others (Chauvé 2008; Alfadl et al. 2013). For example, in  
28      Lebanon, a related study (Sholy 2015) explored the availability of CFM in various households in Lebanon and  
29      found the extent of CFM to range from 3% in Mount Lebanon (ML) to 12% in the Bekaa and South of Lebanon.

30      This study is part of a bigger research programme based on mixed-methods methodology (Hadi and Closs  
31      2016) that included points of interaction between the qualitative (sub-study) and quantitative (bigger study)  
32      components, using the explanatory sequential design. The data in this design are gathered sequentially in two  
33      phases. Phase one (the bigger study) used quantitative research that collected and analysed data from

34 questionnaires (Sholy 2015; Sholy et al. 2017). Phase two is this study (sub-study) used qualitative research  
35 (focus groups) to explain the findings of the questionnaires in phase one (Hadi and Closs 2016).

36 Focus groups (FG) and interviews are both useful qualitative methods (Rabiee 2004; Stewart and  
37 Shamdasani 2014). FG allow participants to listen to the opinion of others, gather views of several people  
38 simultaneously and understand the issues that would not be possible to generate without the interaction  
39 produced from group discussions (Krueger and Casey 2009). FG were used for convenience since they yield a  
40 large amount of data in a short period of time, while the one to one interviews would require more time (Rabiee  
41 2004; Stewart and Shamdasani 2014).

42 There have been limited studies that used FG to explore perceptions about CFM with the public/  
43 pharmacists (Syhakhang et al. 2004). A study in Sudan determined the factors related to CFM purchases using  
44 interviews (Alfadl et al. 2013), and another in Lao People's Democratic Republic (PDR) (Syhakhang et al.  
45 2004) explored the knowledge and perceptions of medicine quality using interviews and FG. Both concluded  
46 that lack of knowledge, high prices and unaffordability of medicines have a major role in increasing the  
47 likelihood of the public using counterfeit or low quality medicine.

48 The findings of a related study (Sholy et al, 2017) suggested exploring the experiences, views and  
49 beliefs of the pharmacists/Public regarding CFM in Lebanon and how they can be limited/controlled.

50

#### 51 **Aim of the study**

52

53 To explore the experiences, views and beliefs of the public and pharmacists regarding CFM.

54

55 **Method**

56

57 This study is descriptive and is based on **phase two** of a mixed-methods methodology, using the explanatory  
58 sequential design. The study used FG as the qualitative method to explore the general public and pharmacists’  
59 experiences, views and beliefs towards CFM. **Phase one** of the study used questionnaires that assessed 849  
60 members of the public (Sholy 2015) and 223 practicing pharmacists on awareness and views towards CFM  
61 (Sholy et al. 2017). The results of phase one showed that the questionnaire did not provide sufficient  
62 information about the components of people’s beliefs and perceptions towards CFM. Therefore, a qualitative  
63 research was necessary to explain and build on the findings of phase one (Hadi and Closs 2016).

64 In order to ensure rigour, trustworthiness, transparency, and integrity of the findings, the methods  
65 required the following:

- 66 • **Triangulation:** the results of phase two illuminated the different perspectives towards CFM problems  
67 identified in phase one (Long and Johnson 2000; Hadi and Closs 2016);
- 68 • **Clarification:** the results of the quantitative method (phase one) using a qualitative method (FG) (Long  
69 and Johnson 2000; Hadi and Closs 2016);
- 70 • **Informed design:** the FG method was based on the findings of the questionnaires, as these provided  
71 information from a large sample of the public about their experiences, views and beliefs of CFM (Long  
72 and Johnson 2000; Hadi and Closs 2016).
- 73 • **Peer debriefing,** the researchers discussed the methodological process with knowledgeable peers on  
74 qualitative research on continuous basis (Long and Johnson 2000; Hadi and Closs 2016).
- 75 • **Participants’ validation,** on completion of the study the findings were checked with participants  
76 (pharmacists only, since the public were difficult to trace back), meeting the diachronic reliability  
77 requirements of the findings, two years after the completion of the study (Long and Johnson 2000; Hadi  
78 and Closs 2016).

79 The results of phase one were adopted using the explanatory sequential design process for developing the  
80 semi-structured guideline questions, for both the public (7 open-ended questions) (**Table 1**) and pharmacists  
81 (8 open-ended questions) (**Table 2**). Follow-up questions were asked to learn more, and probe about topics  
82 that participants brought up.

83

Please insert Table 1 here

84

Please insert Table 2 here

85 **Sample**

86

87 This study was conducted in Lebanon using two public FG with participants from different backgrounds, and  
88 two FG for pharmacists from different pharmacy settings.

89

90 **Public recruitment**

91

92 Two schools in ML were contacted for permission to use their sites. Schools were considered a convenience  
93 sampling method (Profetto-McGrath et al 2010) since it offered easy access to members of the public. The  
94 convenience sample of participants was chosen based on their visits to the principals' offices. The principals  
95 were provided with the following exclusion criteria; any individual who; 1) was younger than 18 years old, 2)  
96 was not living in Lebanon, 3) did not approve of audiotaping the meeting, and 4) not willing to sign the consent  
97 form. The principals' assistants asked each one if they would be interested in participating in the study. Those  
98 willing to participate were asked to register their names on a list with the assistant. Once the date was set, they  
99 were contacted and informed of the set times, and those able to attend were present.

100

101 **Pharmacists' recruitment**

102

103 The recruitment of pharmacists used the snowball approach since the population was hard to reach, or  
104 recruit (Profetto-McGrath et al 2010) due to the sensitivity of the topic, and in order to avoid embarrassing or  
105 coercing pharmacists not willing to participate. The inclusion criterion was any pharmacist practicing in  
106 Lebanon (Lebanese Order of Pharmacists 1994). The exclusion criteria were pharmacists not living in  
107 Lebanon, who did not approve of using the audiotape during the meeting, and who was not willing to sign the  
108 consent form. Once the names were available, each pharmacist was contacted by telephone to explain the  
109 purpose behind the FG meetings. The call was followed by a confirmation email.

110

111 **Data collection**

112

113 The FG took place in the period between April to June 2014. Before starting each meeting, the moderator  
114 reviewed the consent form with participants and encouraged questions before signing the form. At the end of  
115 the meeting participants were given a demographic questionnaire to complete, and the moderator's contact  
116 information for any additional questions.

117           The primary author acted as the moderator for all FG, with the note-taker. Debriefing and observation  
118 discussions took place after each meeting between the moderator and note-taker.

119

## 120 **Data analysis**

121

122 The discussions of the public and pharmacists' FG were transcribed, read and reviewed for each group. The  
123 analysis was performed by the inductive qualitative method followed by a structured process combining  
124 description and interpretation of the data (Kitzinger and Barbour 1999; Profetto-McGrath et al 2010) The  
125 reflexivity of the researchers was addressed by the objectivity of the results of phase one and the research  
126 question, independently of the researcher's background, motives and perspectives. Each FG was analysed  
127 separately and then together (Kitzinger and Barbour 1999; Profetto-McGrath et al 2010) The analytical method  
128 used was thematic/category analysis as described by Kitzinger and Barbour (Kitzinger and Barbour 1999).  
129 With this method a theme is developed based on capturing something important in relation to the researched  
130 topic, irrespective of the number of persons who referred to it (Profetto-McGrath et al 2010). The public  
131 participants were considered aware of the meaning of CFM, if they said it was not the original, fake, or anything  
132 related. For pharmacists, the WHO definition was used as a reference (World Health Organization 2017). From  
133 the FG transcripts, meanings were interpreted, grouped and labelled with a code. The codes were compared  
134 and formed into themes and subthemes (Kitzinger and Barbour 1999; Long and Johnson 2000; Profetto-  
135 McGrath et al 2010; Bellamy et al. 2016). The interpretation of data was based on the "intensity of comments",  
136 "specificity of comments", "internal consistency" and the "big ideas" in link with the research question (Rabiee  
137 2004). The validity of the interpretation is linked to the triangulation method mentioned above to minimize  
138 distortion (Long and Johnson 2000; Profetto-McGrath et al 2010) The relevant quotes were used to support a  
139 theme or an observation.

140 **Results**

141

142 **Public FG**

143

144 The total number of public participants was 23. Their age ranged between 30 and 60, and 21 were female.  
145 Slightly more than one third of participants were between 31- 40 years old. The majority had a university  
146 degree, and lived in the ML region. Lack of awareness dominated the discussion, mixed with helplessness and  
147 mistrust in the system.

148

149 Five main themes emerged from the two public FG discussions detailed in **Table 3** with related quotes.

150

Please insert Table 3 here

151

152 **Pharmacists FG**

153

154 The total number of participants was 13. Their age ranged between 26 and 60, 11 were females, and two thirds  
155 were between 26-30 years old. Participants were mostly from, and practicing in, ML and Beirut. Five worked  
156 with pharmaceutical companies, five in community, two in hospitals and one in both academia and community.  
157 They were motivated to discuss and share their concerns about CFM with other colleagues for the first time.  
158 Frustration and anger dominated the discussion. These emotions were associated with the perceived financial  
159 pressures and lack of professional ethics among pharmacists who deal with CFM.

160

161 Five main themes emerged from the two pharmacist FG discussions detailed in **Table 4** with related quotes.

162

Please insert Table 4 here

163

164 The duration of the discussions for the four FG was between 100-120 minutes.

165

166

167 **Common themes between the public and pharmacists FG**

168

169 **I. Awareness**

170

171 The discussions demonstrated a gap in participants' awareness towards CFM: **1) Defining CFM;** the majority  
172 of public participants were not able to define or provide a meaning to CFM, and either gave false definitions,  
173 or did not know. Pharmacist participants were able to define CFMs and were therefore considered aware of  
174 CFM. **2) Identifying CFM;** a few of public participants were slightly knowledgeable and referred to the  
175 hologram, due to recent media reports. The majority of pharmacists expressed difficulty in identifying CFM,  
176 as they did not rely on the hologram, rather the relied on assessing patients' responses to medicine. **3) CFM**  
177 **reporting System;** No participants were aware of any reporting system, and were not sure how to report  
178 suspected CFM. **4) Prevalence and extent;** according to pharmacist participants, CFM were mostly prevalent  
179 in the northern and southern parts of the country (away from the capital) and close to the borders where there  
180 is less control and implementation of regulations due to the current political situation.

181

182 **II. Trust**

183

184 The four FG participants expressed mistrust and lack of faith towards the system and some pharmacists. **1)**  
185 **The system;** all participants believed that the Ministry of Public Health (MoPH) and the Lebanese Order of  
186 Pharmacists (OPL) were not carrying out their duties as should be, such as providing safe and effective  
187 medicine. Moreover, the public believed that pharmaceutical companies are involved in counterfeiting.  
188 According to pharmacist participants, the distribution channels and wholesalers were not well controlled and  
189 are not to be trusted. This appeared to originate from an incident in 2010 where CFM were available in some  
190 pharmacies through legal channels. Therefore, it would be crucial to control the supply chain. **2) Pharmacists;**  
191 a few of the public participants believed that going to their trusted pharmacist would be one way to avoid  
192 buying CFM, the others distrusted pharmacists and believed they are all involved in the availability of CFM.  
193 The majority of pharmacist participants emphasized how the few pharmacists that were involved in CFM  
194 incidents affected their image, and how difficult it would be to regain the people's respect and trust.

195

196 **III. Corruption**

197

198 All participants expressed their dissatisfaction, and believed the government and regulatory authorities were  
199 manipulating the affairs for private gains. Furthermore, participants stressed the weak implementation and

200 enforcement of the law that in their opinion led to diminished border and customs control. The systems' actions  
201 were not for the public's benefit, especially when no measures were taken against offenders. Pharmacists added  
202 that working in such conditions was becoming very difficult.

203

#### 204 **IV. Overcoming counterfeit medicine**

205

206 Participants suggested that responsible authorities should use different methods to discourage and stop  
207 counterfeiters and the use by the public of CFM. Five subthemes emerged: **1) Education;** the discussions and  
208 exchange of experiences among public participants demonstrated the need to learn and understand more about  
209 CFM and the need for authorities to be more transparent. All pharmacists believed in their need to be educated  
210 and to educate patients about CFM. Pharmacists emphasized the importance of knowledge, stressing the "know  
211 how" that is always missing. The majority of pharmacists raised the concern that physicians should also be  
212 aware and educated regarding CFM, as there seemed to be a lack of awareness among physicians. **2) Laws  
213 and regulations;** all participants agreed on the need for laws and regulations to be implemented and enforced.  
214 In addition, there is a need to develop a CFM reporting system and a point of reference where the MoPH and  
215 OPL can be available and involved. **3) Responsibility and accountability;** the public participants believed  
216 that naturally the MoPH should be responsible for guaranteeing that safe and effective medicine to reach  
217 pharmacies. They suggested using different methods to discourage and stop counterfeiters. **4) Central  
218 laboratory;** all pharmacists highlighted the need for the MoPH to reactivate the national laboratory, to  
219 randomly test samples of medicine in the country. **5) Dedicated pharmacists;** the majority of pharmacists  
220 believed they could have a major role in controlling the availability of CFM, through organizing and  
221 controlling the pharmacy profession, to stop the outliers.

222

#### 223 **Uncommon themes**

224

#### 225 **V. Locus of control**

226

227 This theme reflected the degree that participants' perceived events to be under their control (internal) or under  
228 the control of others who are more powerful (external) as the following subthemes: **1) Internal control;**  
229 participants' believed that controlling the events and outcomes themselves were dependent on their knowledge.  
230 The majority highlighted that people in general lacked enough knowledge about medicine, and thus did not  
231 know what to do. **2) External control;** participants' believed they did not have the power to control events or  
232 outcomes, rather relying on outside influences or external factors such as other people, government, or fate.



233 These external factors were subdivided into: **a) Worries;** participants' worries and concerns relating to the  
234 outcome of their medicine if counterfeit. **b) Financial concern;** the high cost of medicine was the reason  
235 behind the availability of CFM. Patients would unknowingly go for a cheaper medicine if given a choice. **c)**  
236 **Political instability;** the majority of participants seemed overwhelmed with the country's political instability,  
237 and did not consider CFM a priority for the government or politicians. Participants considered themselves  
238 unworthy of "good" medicine.

239

## 240 **VI. Reasons for availability of CFM**

241

242 The following subthemes emerged while pharmacists' FGs were describing the reasons for CFM availability:

243 **1) Pharmacists;** for the following reasons: **a) Business and profit;** the majority believed that there are some  
244 unethical pharmacists who do not care, and each community has pharmacists that deal with CFM, thus  
245 contributing to the mistrust of pharmacists. Moreover, some pharmacists illegally discounted the medicine  
246 priced by the MoPH to appear more compassionate towards patients, when the discounted medicine may be  
247 counterfeit. **b) Professional experience;** participants shared their experiences about being approached and  
248 offered CFM. Participants reported how dealers always checked around and offered CFM to those interested,  
249 and would target new pharmacies, young graduates or the inexperienced for their tendency to be more  
250 vulnerable than others. Older participants stated they were also approached when they opened their pharmacies,  
251 and due to their continuous rejections, were no longer approached. **2) Medicine shortages;** the majority  
252 believed that counterfeiters took advantage of medicine shortages and offered cheaper alternatives or provided  
253 attractive offers for medicine that could only be counterfeit. **3) Demand;** the majority reported in believing  
254 that patients end up buying CFM due to the high cost of medicine, and the financial situation caused by the  
255 political instability. Participants believed that some members of the public may be aware but do not care and  
256 choose the cheaper medicine (CFM), and some lack awareness. **4) Control;** participants reported that their  
257 concerns were due to the MoPH's lack of control of available medicine and the supply chain. Pharmacists  
258 expressed that they had limited control and were under a lot of pressure.

259

260 The structure of the thematic network for the four FG is presented in Fig1.

261

Please insert Fig 1 here

262

263 **Discussion**

264

265 The study explored the views, experiences, and beliefs of the public and pharmacists towards CFM using FG.  
266 The study applied the mixed methods methodology using both quantitative and qualitative research. Four  
267 common themes emerged among all participants indicating the similar views and beliefs about CFM, reflecting  
268 their own perceptions and experiences. The discussions showed a lack of experience and limited awareness  
269 regarding CFM among the public, however pharmacists were aware but the level of expertise appeared related  
270 to the number of years in practice. The study sample for all groups had an over-representation of females, thus  
271 the results might be gender specific, as studies show that males and females do have different views and beliefs  
272 (Abbey 1982).

273

274 **Contributing factors to CFM**

275

276 No participants were aware of the CFM reporting system, and considered the pharmacy a reasonable place for  
277 reporting suspected CFM. One study also expressed pharmacists' need for an official CFM reporting system,  
278 and also counselling patients about the system and CFM (Jackson et al. 2012; Sholy et al. 2017). Moreover,  
279 pharmacists indicated that CFM were more prevalent in the North, South, and Bekaa in accordance with phase  
280 one of the study (Sholy 2015) where the extent of CFM ranged from 3% in ML to 12.1% in the South and the  
281 Bekaa. The difficulty expressed by participants in identifying CFM was supported by other studies on how  
282 easy it is becoming to counterfeit (Kitzinger and Barbour 1999; Deisingh 2005; Newton et al. 2006; Sholy  
283 2015).

284 The mistrust towards the MoPH, OPL, pharmacists, regulatory authorities and pharmaceutical companies  
285 was probably due to what participants considered lack of transparency and professional misconduct. The  
286 findings were in accordance with the WHO which states that counterfeiting is contributing to the damaging of  
287 the reputation of pharmaceutical companies by destroying public confidence and trust in medicine, which  
288 causes the reluctance of some companies to publicize incidents of their products being counterfeited (Kahn et  
289 al. 2012).

290 The continuous increase in the number of graduating pharmacists' year on year was reported to have  
291 decreased pharmacists' minimum wages to \$1350/month (Lebanese Order of Pharmacists 2014) which might  
292 have contributed to some pharmacists being involved in the reported incidents involving CFM (Sholy et al.  
293 2017). Many studies have documented the impact pharmacists can play in improving patients' health outcome,  
294 and decreasing the chances of dispensing CFM (Chauvé 2008; Law and Youmans 2011; Jackson et al. 2012;  
295 Alfadl et al. 2013; Rajapandian et al. 2013; Mdege et al. 2016). However, the good or bad headlines do

296 influence the perception of the pharmacy profession, therefore, more efforts are required to enhance the  
297 reputation of the profession, and improve pharmacists' image to regain the trust of the public (DiPiro 2011).

298 Trust is an important asset the public can give to healthcare professionals when their work is for furthering  
299 social justice and public health (Kass 2001). According to the UK code of ethics, the public need to trust that  
300 they are pharmacists' primary concern, and that pharmacists are honest, trustworthy, and protective of patients  
301 from any harm by providing safe and effective medicine (General Pharmaceutical Council 2017). To date,  
302 there is no known or published code of ethics for pharmacists in Lebanon; consequently, the OPL should  
303 consider agreeing on a code that all registered pharmacists must follow (Sholy et al. 2017).

304 The mistrust theme is related to corruption according to a study that measured the degree of trust in  
305 societies around the world, which varied considerably and was strongly correlated with views about crime and  
306 corruption (Wike and Holzwart 2008). The study also reported that 67% of the Lebanese respondents disagreed  
307 that most people in society are trustworthy, compared to Egypt (40%), Jordan (45%) and Kuwait (71%).  
308 Moreover, the Lebanese and Nigerian's trust was rare due to respondents' reported concern about widespread  
309 of political corruption. In fact, in countries where people reported trusting each other, there were less worries  
310 about crime or corrupt political leaders (Wike and Holzwart 2008). This study's participants stated the need  
311 for clear laws to be implemented and enforced, although they did not believe that their suggestions would be  
312 implemented or would change anything, since corruption is so deeply rooted in the culture. Cultures of  
313 corruptions will not fade away (Tanzi 1998) and according to participants, this is the case in Lebanon.

314 Consequently, the belief that corruption had a role in the availability of CFM is also reported in the USA  
315 and UK, where corruption among wholesalers and illegal supply chains allowed CFM to enter their legal chain  
316 system (Besançon 2008; Mackey et al. 2015). The problem of medicine shortage in Lebanon is also a global  
317 concern that counterfeiters take advantage of (Newton et al. 2006) as they use original holograms on  
318 counterfeits (Sholy 2015). This would explain why pharmacists reported not relying on holograms.  
319 Furthermore, participants stated that shortage of medicine increases the demand for cheaper medicine which  
320 are highly likely to be counterfeits, which is supported by a number of studies (Chauvé 2008; Alfadl et al.  
321 2013; Rajapandian et al. 2013; Mdege et al. 2016). In Poland, people who had low monthly income found the  
322 low cost of CFM attractive, and consciously bought them due to their availability and low cost, increasing the  
323 demand for CFM (Binkowska-Bury et al. 2013).

324

### 325 **Overcoming factors to CFM**

326

327 Participants also emphasised the need for the government to develop legal frameworks and strong legislations

328 regulating medicine, with severe penalties to deter counterfeiters, as supported by several other studies  
329 (Syhakhang et al 2004; Chauvé 2008; Alfadl et al. 2013; Al-Worafi 2014; Mdege et al. 2016). Their  
330 suggestions were in support of the OPL with pharmacists being positioned at customs and within hospitals.  
331 There were also further suggestions to reactivate the national laboratory to test and control supply chain of all  
332 medicines in the Lebanese market, to ensure safety (Chauvé 2008; Lebanon Pharmaceuticals and Healthcare  
333 2010; Rajapandian et al. 2013; Sholy et al. 2017).

334 All participants indicated that education was key, and considered education the turning point for  
335 controlling CFM availability as supported by other studies (Alfadl et al. 2013; El Jardali et al. 2015; Sholy et  
336 al. 2017). Participants demonstrated the need to establish a centralized and standardized reporting system, such  
337 as Medwatch that encourages voluntary reporting of suspected CFM (U.S. Food and Drug Administration  
338 2016). The burden of CFM can then be estimated by costs of hospitalizations or ambulatory settings for treating  
339 the consequences of CFM use (Akiny 2013).

340 Identifying the appropriate interventions required for the educational, managerial and regulatory programs  
341 may lead to the development of beneficial interventions. Additionally, pharmacists' awareness and CFM  
342 education can play a key role in educating and counselling patients about CFM that can empower the public  
343 by decreasing their vulnerability towards CFM, improving detection and reporting of CFM, thus reducing their  
344 availability/use.

345

#### 346 **Limitations**

347

348 When approached, not all pharmacists were enthusiastic or willing to participate in the study. The FG were  
349 conducted in ML, the region with the lowest incidences of CFM use. There was a bias in the sample of the  
350 public participants, as the majority had university degrees, were females and were in the same age group.

351 **Conclusion**

352 This is the first FG study to generate insight on awareness among the public, and pharmacists regarding CFM  
353 in Lebanon. The results were consistent with previous studies on the need for changes related to regulations,  
354 enforcement of the law, and updating pharmacists' CFM knowledge. Additionally, emphasised the role of high  
355 prices and the unaffordability of medicines in increasing vulnerability of the public to using CFM. Finally,  
356 there is a need for future mixed methods research to assess and confirm the themes suggested in this study.

357 **Ethics approval**

358

359 The School of Pharmacy and Biomolecular Sciences Research Ethics Committee at the University of Brighton

360 approved the study.

361

- 363 1. Abbey A (1982) Sex differences in attributions for friendly behavior: Do males misperceive females'  
364 friendliness? *J Pers Soc Psychol.* 42(5): 830.
- 365 2. Akiny O (2013) Counterfeit drugs in Nigeria: A threat to public health. *Afr J Pharm Pharmacol.* 7(36):  
366 2571-2576.
- 367 3. Al-Worafi YM (2014) Pharmacy practice and its challenges in Yemen. *Australas Med J.* 7(1): 17
- 368 4. Alfadl AA, Hassali MA, Ibrahim MI (2013) Counterfeit drug demand: perceptions of policy makers and  
369 community pharmacists in Sudan. *Res Social Adm Pharm.* 9(3): 302-10.
- 370 5. Bellamy K, Ostini R, Martini N, Kairuz T (2016) Seeking to understand: using generic qualitative research  
371 to explore access to medicines and pharmacy services among resettled refugees. *Int J Clin Pharm.* 38(3):  
372 671-675.
- 373 6. Besançon L (2008) The role of hospital pharmacists in counterfeit medicines. *Eur J Hosp Pharma.* 14(2):  
374 65-66. Available at: <https://www.fip.org/files/fip/HospPharmCountMedLuc.pdf>. Accessed October 2016.
- 375 7. Binkowska-Bury M, Januszewicz P, Wolan M, Sobolewski M, Krauze M, Fijalek ZE (2013) Counterfeit  
376 medicines in Poland: Opinions of primary healthcare physicians, nurses and lay persons. *J Clin Nurs.* 22(3-  
377 4): 559-568.
- 378 8. Bird RC (2007) Counterfeit drugs: a global consumer perspective. *Wake Forest Intellect Prop Law J.* 8(3):  
379 387-406. Available  
380 at: <http://heinonline.org/HOL/LandingPage?handle=hein.journals/wakfinp8&div=19&id=&page=->.  
381 Accessed October 2016.
- 382 9. Chauvé M (2008) La lutte contre la contrefaçon de médicaments en Afrique: expériences et rôle des  
383 pharmaciens. *Comptes Rendus Biologies.* 331(12): 982-5.
- 384 10. Deisingh AK (2005) Pharmaceutical counterfeiting. *Analyst.* 130(3): 271-279. Available  
385 at: <http://www.rsc.org/analyst>. Accessed 2010.
- 386 11. DiPiro JT (2011). Preparing our students for the many opportunities in pharmacy. *Am J Pharm Educ.*  
387 75(9): 170.
- 388 12. El-Jardali F, Akl EA, Fadlallah R, Oliver S, Saleh N, El-Bawab L, et al (2015) Interventions to combat or  
389 prevent drug counterfeiting: a systematic review. *BMJ open.* 5(3): e006290.
- 390 13. General Pharmaceutical Council. Standards of conduct, ethics and performance. May 2017. Available  
391 at: <https://www.pharmacyregulation.org/standards>. Accessed June, 2017.
- 392 14. Hadi MA, Closs SJ (2016) Applications of mixed-methods methodology in clinical pharmacy research.  
393 *Int J Clin Pharm.* 38(3): 635-640.  
394 [https://www.researchgate.net/profile/Judith\\_Zaichkowsky/publication/225677170\\_Brand\\_Imitation\\_Do](https://www.researchgate.net/profile/Judith_Zaichkowsky/publication/225677170_Brand_Imitation_Do_the_Chinese_Have_Different_VIEWS/links/554d25690cf29f836c9cd7e1.pdf)  
395 [the\\_Chinese\\_Have\\_Different\\_VIEWS/links/554d25690cf29f836c9cd7e1.pdf](https://www.researchgate.net/profile/Judith_Zaichkowsky/publication/225677170_Brand_Imitation_Do_the_Chinese_Have_Different_VIEWS/links/554d25690cf29f836c9cd7e1.pdf). Accessed October 2016.
- 396 15. Jackson G, Patel S, Khan S (2012) Assessing the problem of counterfeit medications in the United  
397 Kingdom. *Int J Clin Pract.* 66(3): 241-250.
- 398 16. Kahn U, Kreutzer S, Gill J, Taylor D (2012) Falsified medicines and the global public's health. Report of  
399 Matrix Insight and UCL School of Pharmacy. Nov.
- 400 17. Kass NE (2001) An ethics framework for public health. *Am. J. Pharm. Educ.* 91(11): 1776-1782. Abstract  
401 available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1446875/?tool=pmcentrez>. Accessed  
402 October 2016.
- 403 18. Kitzinger J, Barbour R, editors (1999) Developing focus group research: politics, theory and practice.  
404 Sage Publications.
- 405 19. Krueger RA, Casey MA (2009) Focus Groups: A practical guide for applied research. A practical guide  
406 for applied research. 4th ed. Los Angeles: Sage Publication.
- 407 20. Lai KK, Zaichkowsky JL (1999) Brand imitation: do the Chinese have different views?. *Asia Pac J Man.*  
408 16(2): 179-92. Available at:
- 409 21. Law E, Youmans SL (2011) Combating counterfeit medications: The California pharmacist perspective.  
410 *J Pharm Pract.* 24(1): 114-121.
- 411 22. Lebanese Order of Pharmacists (1994) Laws and regulations Law 367. Available  
412 at: [https://secure58.prositehosting.co.uk/site/en/lois.php?pageId=8&catId=2&sliderId=4&sliderLinkId=](https://secure58.prositehosting.co.uk/site/en/lois.php?pageId=8&catId=2&sliderId=4&sliderLinkId=19)  
413 [19](https://secure58.prositehosting.co.uk/site/en/lois.php?pageId=8&catId=2&sliderId=4&sliderLinkId=19). Accessed November 2014.
- 414 23. Lebanese Order of Pharmacists (2014) Press conference, 20-06-2014. Available  
415 at: <http://www.opl.org.lb/newdesign/lawsandregulations.php>. Accessed June 2017.
- 416 24. Lebanon Pharmaceuticals and Healthcare (2010) Report Q2 2010. ReportLinker. Published on March  
417 2010. Report Summary. Available at: [http://www.slideshare.net/ReportLinker/lebanon-pharmaceuticals-](http://www.slideshare.net/ReportLinker/lebanon-pharmaceuticals-and-healthcare-report-q2-2010)  
418 [and-healthcare-report-q2-2010](http://www.slideshare.net/ReportLinker/lebanon-pharmaceuticals-and-healthcare-report-q2-2010). Accessed June 2017.
- 419 25. Long T, Johnson M (2000) Rigour, reliability and validity in qualitative research. *Clin Eff Nurs.* 4(1): 30-  
420 37.
- 421 26. Mackey TK, Cuomo R, Guerra C, Liang BA (2015) After counterfeit Avastin [reg][mdash] what have we  
422 learned and what can be done?. *Nat. Rev. Clin. Oncol.* 12(5): 302-8.
- 423 27. Mdege ND, Chevo T, Toner P (2016) Perceptions of current and potential public health involvement of  
424 pharmacists in developing nations: The case of Zimbabwe. *Res Social Adm Pharm.* 12(6): 876-84.

- 425 28. Newton PN, Green MD, Fernández FM, Day NP, White NJ (2006) Counterfeit anti-infective drugs. *Lancet*  
426 *Infect Dis.* 6(9): 602-613.
- 427 29. Profetto-McGrath J, Polit DF, Beck CT (2010) *Canadian essentials of nursing research*. Lippincott  
428 Williams & Wilkins.
- 429 30. Rabiee F (2004) Focus-group interview and data analysis. *Proceedings of the nutrition society.* 63(04):  
430 655-660.
- 431 31. Rajapandian G, Narayanan N, Maheswaran A, Chanchal P (2013) Dangerous world of counterfeit drugs-  
432 pharmacist's role and its prevention. *I J Pharm Sci Res.* 4(5): 1709.
- 433 32. Sholy LB (2015) *Nature, extent, awareness, and attitudes towards counterfeit medicine in Lebanon*.  
434 Doctoral dissertation. University of Brighton. Available at: <http://eprints.brighton.ac.uk/15755/>.  
435 Accessed October, 2016.
- 436 33. Sholy LB, Gard PR, Williams S, MacAdam A (2017) Pharmacist Awareness and Views Towards  
437 Counterfeit Medicine in Lebanon. *Int J Pharm Pract.* Accepted June 9, 2017 and pending publication.
- 438 34. Stewart DW, Shamdasani PN (2014) *Focus groups: Theory and practice* (Vol. 20). Thousand Oaks: Sage  
439 Publications.
- 440 35. Syhakhang L, Freudenthal S, Tomson G, Wahlström R (2004) Knowledge and perceptions of drug quality  
441 among drug sellers and consumers in Lao PDR. *Health Policy Plan.* 19(6): 391-401.
- 442 36. Tanzi V (1998) Corruption around the world: Causes, consequences, scope, and cures. *Staff Papers-*  
443 *International Monetary Fund.* 45(4): 559-94.
- 444 37. U.S. Food and Drug Administration (2016) Reporting serious problems to FDA. Available  
445 at: <http://www.fda.gov/Safety/MedWatch/HowToReport/>. Accessed June 2017.
- 446 38. United Nations Office on Drug and Crime (UNODC) (2006) Counterfeit products. Available  
447 at: [https://www.unodc.org/documents/data-and-analysis/tocta/8.Counterfeit\\_products.pdf](https://www.unodc.org/documents/data-and-analysis/tocta/8.Counterfeit_products.pdf). Accessed  
448 June 2017.
- 449 39. Wike R, Holzwart K (2008) Where Trust is High, Crime and Corruption are Low—Since Communism's  
450 Fall, Social Trust Has Fallen in Eastern Europe. Pew Global Attitudes Project.
- 451 40. World Health Organization (2017) Spurious/false-labelled/falsified/counterfeit (SFFC) medicines.  
452 Available at: <http://www.who.int/mediacentre/factsheets/fs275/en/>. Accessed June 2017.